COAG (Hemab Therapeutics Holdings) Other Current Liabilities: $3.01 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COAG Hemab Therapeutics Holdings Inc COAG
11 GF Score
Price $49.66
! 2 Warning Signs
View Full Analysis

What is Hemab Therapeutics Holdings Other Current Liabilities?

Hemab Therapeutics Holdings COAG -4.44% 11 Other Current Liabilities is $3.01 Mil as of Dec. 2025. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Hemab Therapeutics Holdings's other current liabilities for the quarter that ended in Dec. 2025 was $3.01 Mil.

Hemab Therapeutics Holdings's quarterly other current liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($1.67 Mil) and increased from Dec. 2024 ($1.67 Mil) to Dec. 2025 ($3.01 Mil).

Hemab Therapeutics Holdings's annual other current liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($1.67 Mil) and increased from Dec. 2024 ($1.67 Mil) to Dec. 2025 ($3.01 Mil).

Hemab Therapeutics Holdings Other Current Liabilities Related Terms

Hemab Therapeutics Holdings Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Hemab Therapeutics Holdings's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemab Therapeutics Holdings Other Current Liabilities Chart

Hemab Therapeutics Holdings Annual Data
Trend Dec24 Dec25
Other Current Liabilities
1.67 3.01

Hemab Therapeutics Holdings Semi-Annual Data
Dec24 Dec25
Other Current Liabilities 1.67 3.01
COAG
11GF Score
Hemab Therapeutics Holdings Inc COAG
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemab Therapeutics Holdings Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $3.01 Mil mean?
Hemab Therapeutics Holdings (COAG) has a Other Current Liabilities of $3.01 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Hemab Therapeutics Holdings.
Is Hemab Therapeutics Holdings' Other Current Liabilities too high?
Hemab Therapeutics Holdings' current Other Current Liabilities is $3.01 Mil. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Other Current Liabilities compare to ZLAB and SLS?
Hemab Therapeutics Holdings' Other Current Liabilities of $3.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Hemab Therapeutics Holdings. Hemab Therapeutics Holdings's current Other Current Liabilities is $3.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Other Current Liabilities of $3.01 Mil. The current Other Current Liabilities is $3.01 Mil. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Other Current Liabilities is $3.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemab Therapeutics Holdings Business Description

Address 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score

Get the complete analysis for COAG

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$49.66
Price